Furthermore, the interplay between IFNβ and IL-6 is likely to be affected in the context of the use of jakinibs, small-molecule therapeutics for autoimmune disease that inhibit the activity of one or more of the Janus kinase (JAK) enzymes to shape the STAT signaling in immune cells (50, 51). Here, SOAT1 is linked to autoimmune disease.